Skip to content
Screener

Nuvation Bio NUVB Common Stock Shares Issued

Common Stock Shares Issued at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
18.3M+3.4%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
14.6M+0.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
127M+19.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+22.7%
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.32B+202%
Enterprise value$2.07B+259%
P/S13.6×-39.8×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Nuvation Bio’s 10-K, filed March 2, 2026.

Filed
Mar 2, 2026, 4:49 PM EST
Fiscal year
FY2025
Accession
0001193125-26-085584
Line itemDecember 31, 2025December 31, 2024
Total liabilities289,10676,838
Commitments and contingencies (Note 16)
Stockholders’ equity`
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of December 31, 2025 and December 31, 2024, 346,503,675 (Class A 345,503,675, Class B 1,000,000) and 337,837,872 (Class A 336,837,872, Class B 1,000,000) shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively1,421,2731,373,958
Accumulated deficit(1,115,370)(910,743)
Accumulated other comprehensive income(187)573
Total stockholders’ equity305,716463,788
Total liabilities and stockholders’ equity$594,822$540,626

Item 16. Form 10K Summary

FAQ

What is Nuvation Bio's common stock shares issued?
Nuvation Bio (NUVB) reported common stock shares issued of 337.8M in Q4 2025.
How has Nuvation Bio's common stock shares issued changed year-over-year?
Nuvation Bio's common stock shares issued decreased by 0.0% year-over-year, from 337.8M to 337.8M.
What is the long-term trend for Nuvation Bio's common stock shares issued?
Over 5 years (2020 to 2025), Nuvation Bio's common stock shares issued has grown at a 17.8% compound annual growth rate (CAGR), from 149M to 337.8M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Nuvation Bio's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude